secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0000917520-25-000094
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences Q3 revenue $402.1M, adjusted EPS $0.54; cuts full-year guidance
--------------------------------------------------------------------------------

- Q3 reported revenues $402.1M, +5.6% YoY; organic growth 5.0%.
- GAAP net loss $(5.4)M ($(0.07)/diluted share); adjusted EPS $0.54 vs $0.41 YoY.
- Codman Specialty Surgical revenues $292.6M (+8.1% reported); Tissue Technologies $109.5M (-0.5% reported).
- Full-year 2025 revenue guidance cut to $1.620B-$1.640B (organic growth -1.6% to -0.4%); adj EPS $2.19-$2.24.
- Relaunched PriMatrix and Durepair ahead of schedule; Braintree facility on track for production in June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752025000094/0000917520-25-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752025000094/iart-20251030.htm
  HTML page:      https://secwatch.observer/filing/0000917520-25-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer